Campylobacter

Phase Genomics Announces Funding to Accelerate Discovery of New Lysin-Based Precision Antimicrobials

Retrieved on: 
Tuesday, March 5, 2024
Science, Other Science, Biotechnology, Research, General Health, Health, Infectious Diseases, Genetics, Therapy, Campylobacter, Doctor of Philosophy, NIH, Collateral damage, News, Lysin, Bacteria, Ruminant, Environmental health, Virus, Genomics, Phase Genomics, Bill, Archaea, Melinda French Gates, AMR

Phase Genomics, Inc. , a leading innovator at the forefront of genomics technology development, today announced $1.5MM in new funding from the Bill & Melinda Gates Foundation to fuel a new antimicrobial discovery platform.

Key Points: 
  • Phase Genomics, Inc. , a leading innovator at the forefront of genomics technology development, today announced $1.5MM in new funding from the Bill & Melinda Gates Foundation to fuel a new antimicrobial discovery platform.
  • The foundation of this effort rests on Phase Genomics’ proprietary global phage atlas, developed with support from the Gates Foundation and the NIH.
  • Under this project, Phase Genomics will deploy its platform to develop antimicrobial agents that bypass resistance against Campylobacter infections and methanogenic archaea in ruminants that drive global methane emissions.
  • Follow Phase Genomics on X and LinkedIn for the latest news and information.

Immuron Clinical Trials Update

Retrieved on: 
Friday, December 22, 2023
Spore, Clostridioides difficile, ASX, Immuron, Principal, Diarrhea, FDA, NMRC, Campylobacter, IMC, Johns Hopkins University, Trial of the century, MD, Agriculture, Clinical trial, GLP, Volunteering, Escherichia, Escherichia coli, CIR, CHIM, Patient, Monash University, Safety, JHU, Clostridioides, Pharmaceutical industry

MELBOURNE, Australia, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to provide shareholders and the market with an update on the company’s clinical development portfolio.

Key Points: 
  • The NMRC has recently completed the in-patient stage of the campylobacter challenge clinical study.
  • Headline results from the clinical trial are anticipated to be reported in H2 2024.
  • The Phase 2 clinical trial is designed to evaluate the safety and protective efficacy of the new product manufactured by Immuron compared to a placebo in a controlled human infection model (CHIM).
  • The inpatient challenge phase of the Travelan clinical study led by Principal Investigator Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US, has been completed.

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Retrieved on: 
Monday, December 4, 2023
ASX, Immuron, Principal, IBS, Diarrhea, NMRC, ETEC, Campylobacter, Disease, IMC, Trial of the century, Johns Hopkins University, MD, Clinical trial, Enterotoxigenic Escherichia coli, Infection, Morale, CIR, CHIM, Gastroenteritis, Safety, JHU, Judgement, Pharmaceutical industry

MELBOURNE, Australia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that the US Naval Medical Research Command (NMRC) has initiated the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron. The NMRC has prioritized the clinical development of the study to evaluate the efficacy of the new therapeutic product to prevent infectious diarrhea caused by Campylobacter.

Key Points: 
  • The NMRC has prioritized the clinical development of the study to evaluate the efficacy of the new therapeutic product to prevent infectious diarrhea caused by Campylobacter.
  • The clinical study is being led by Principal Investigator Dr Kawsar Talaat, MD at the Johns Hopkins University (JHU) Center for Immunization Research (CIR) Inpatient Unit, located at the JHU Bayview Medical Campus, Baltimore, Maryland.
  • The dosing, challenge and the in-patient stage of the study is anticipated to be completed by the third week of December 2023.
  • The estimated study completion date (last participant, last visit) is June 2024 with headline results from the clinical trial expected to be reported in 2H 2024.

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Retrieved on: 
Monday, October 30, 2023
Other Natural Resources, Health, Natural Resources, Pharmaceutical, Biotechnology, Veterinary, Food safety, Escherichia coli, Incidence, Bird, Human, Poultry, Diarrhea, Weight loss, Mortality, Digestion, Prevalence, Salmonella, Coccidiosis, Clostridium perfringens, Campylobacter, Chicken, Disease, Partnership, Drug resistance, Fungal infection, Poultry farming

This new study will be performed under the same conditions as the previous 28-day coccidiosis challenge study, but will be carried out for the full 42-day grow out period typical in the broiler production industry.

Key Points: 
  • This new study will be performed under the same conditions as the previous 28-day coccidiosis challenge study, but will be carried out for the full 42-day grow out period typical in the broiler production industry.
  • “Our coccidiosis product candidate holds potential to transform poultry health management.
  • Products for treating coccidiosis are mostly antibiotic- or ionophore-based, and no significant new commercial technology has been introduced in the past 60 years.
  • Coccidiosis is a common disease for chickens, especially among young chicks, and can be fatal or result in compromised digestion.

Food Diagnostics Market worth $23.5 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, November 1, 2023
System, BioMérieux, Laboratory, FDA, Shimadzu, Food safety, Escherichia coli, CFIA, Tradition, Health, Food, Pesticide, Poultry, Meat, Region, Salmonella, PCR, Dairy, Cereals & Grains Association, Campylobacter, Growth, Thermo Fisher Scientific, Cereal, Agilent Technologies, Risk, Allergen, Merck Group, Standard Barrel Act For Fruits, Vegetables, and Dry Commodities, Food quality, USD, Public, Safety, QIAGEN, Vegetable, Pharmaceutical industry, Pet industry, Medical device, Listeria, Seafood

Food diagnostics involves a range of techniques and technologies used to detect contaminants, pathogens, allergens, and adulterants in food products.

Key Points: 
  • Food diagnostics involves a range of techniques and technologies used to detect contaminants, pathogens, allergens, and adulterants in food products.
  • By food tested, the fruits & vegetables segment is anticipated to grow at a significant rate in the food diagnostics market.
  • North America is estimated to have a significant market share in the global food diagnostics market.
  • Consequently, the market for food diagnostics services has witnessed substantial growth as it offers consumers the assurance and peace of mind they seek when making food choices.

Top 10 Food Safety Testing and Technologies Trends worth $33.7 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, October 27, 2023
Food safety, Food industry, Intertek, International, Tradition, Genetically modified organism, Substrate, Poultry, Meat, Region, Salmonella, PCR, Dairy, GMO, SGS, Cereals & Grains Association, Campylobacter, Growth, Thermo Fisher Scientific, ALS, Bureau Veritas, Marketing, Standard Barrel Act For Fruits, Vegetables, and Dry Commodities, AsureQuality Limited, Label, Medical device, Agriculture, Listeria, Immunoassay, Allergen, Mycotoxin

These include the global nature of the food supply chain has increased the complexity of ensuring food safety.

Key Points: 
  • These include the global nature of the food supply chain has increased the complexity of ensuring food safety.
  • With food products crossing international borders, there is a need for standardized testing and quality assurance protocols to ensure that products meet safety standards.
  • The largest growing trend in the food safety testing market is food pathogen, which is estimated to be the most significant market.
  • The GMO food safety testing market is projected to stand second, in terms of the fastest-growing trends, during the forecast period from 2023 to 2028.

Top 10 Food Safety Testing and Technologies Trends worth $33.7 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, October 27, 2023
Food safety, Food industry, Intertek, International, Tradition, Genetically modified organism, Substrate, Poultry, Meat, Region, Salmonella, PCR, Dairy, GMO, SGS, Cereals & Grains Association, Campylobacter, Growth, Thermo Fisher Scientific, ALS, Bureau Veritas, Marketing, Standard Barrel Act For Fruits, Vegetables, and Dry Commodities, AsureQuality Limited, Label, Medical device, Agriculture, Listeria, Immunoassay, Allergen, Mycotoxin

These include the global nature of the food supply chain has increased the complexity of ensuring food safety.

Key Points: 
  • These include the global nature of the food supply chain has increased the complexity of ensuring food safety.
  • With food products crossing international borders, there is a need for standardized testing and quality assurance protocols to ensure that products meet safety standards.
  • The largest growing trend in the food safety testing market is food pathogen, which is estimated to be the most significant market.
  • The GMO food safety testing market is projected to stand second, in terms of the fastest-growing trends, during the forecast period from 2023 to 2028.

The sniff test is not reliable for food safety – here's why

Retrieved on: 
Tuesday, August 22, 2023
Smell, Food, Campylobacter, Bad breath, Flatulence, Fruit, Carbon, Element, Vegetable, Milk, Nose, Metabolism, Cooking, Time, Risk, Smoke, Bacteria, Salt, Family, Aroma compound, Food preservation, Listeria, Salmonella

I’ve just pulled some sliced chicken out of the fridge, as I set out to make up some sandwiches.

Key Points: 
  • I’ve just pulled some sliced chicken out of the fridge, as I set out to make up some sandwiches.
  • Another member of the family has unlovingly ripped open the packaging and the slices have been sitting exposed in the fridge for several days.
  • Wondering if the chicken is still usable, I give it a good sniff, hoping for some evidence that it is still good or has gone off.
  • Yet, there I am, trying and failing to give myself confidence with the old sniff test.

Spoiled food can smell, though

    • But it is possible to detect when food is spoiled – another action of microbes, as they eat away at food that has been left for too long or has been in the wrong storage conditions.
    • This is one of the reasons why a more appropriate use of the sniff test is to suss out spoiled milk and help limit food waste, rather than throw out milk that might otherwise be safe.
    • And for some foods – think of the microbial contribution to the finest cheeses – it is a culinary attribute to be malodorous.

Immuron to present at the Military Health System Research Symposium

Retrieved on: 
Monday, August 14, 2023
Immuron, IMC, Naval Medical Research Center, Enterotoxigenic Escherichia coli, U.S. Department of Defense Strategy for Operating in Cyberspace, Diarrhea, Campylobacter, Gastroenteritis, ETEC, ASX, Traveler, Judgement, Development, IBS, Disease, NMRC, Poster, Morale, MTEC, Pharmaceutical industry

The company will attend the meeting as an Exhibitor and present two posters at the event.

Key Points: 
  • The company will attend the meeting as an Exhibitor and present two posters at the event.
  • One entitled ‘Clinical Evaluation of an Oral prophylactic for prevention of Travelers diarrhea in active-duty military assigned abroad’.
  • The Naval Medical Research Center (NMRC) are also presenting a poster at the symposium on the new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron.
  • The NMRC poster is entitled ‘Research and Development of Hyperimmune Bovine Colostrum Products for the Prevention of Travelers’ Diarrhea’.

Spectacular Labs Unveils Future of Food Safety Testing

Retrieved on: 
Wednesday, July 12, 2023
Retail, Health, Supply Chain Management, Restaurant, Bar, Transport, Other Science, Research, Other Retail, General Health, Supermarket, Specialty, Science, Logistics, Food, Beverage, Cloud, International Association for Food Protection, IAFP, University, Workflow, Berkeley, Farmer, Food safety, Campylobacter, International Association, Doctor of Philosophy, Laboratory, Annual general meeting, Stockholm Environment Institute US Center, Labs, Entrepreneurship, Salmonella, Corona Labs Inc., Escherichia coli, Pharmaceutical industry, Vaccine, Listeria

Food and beverage companies will be able to detect pathogens on-site easily, and testing laboratories will be able to scale operations cost-effectively.

Key Points: 
  • Food and beverage companies will be able to detect pathogens on-site easily, and testing laboratories will be able to scale operations cost-effectively.
  • Spectacular Labs was founded in 2020 by scientists out of the University of California, Berkeley, to create an innovative pathogen detection platform that reduces inefficiencies and modernizes current testing workflows.
  • Spectacular Labs was the first company to fully automate the foodborne pathogen testing workflow from enrichment to reporting.
  • "Spectacular Labs is poised to modernize the traditional food safety testing process with a complete pathogen detection platform that accelerates turnaround times, automates workflows, and eliminates costly supply chain bottlenecks,” said George Powlick, Partner at Astanor Ventures.